Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab Phase 2b in Psoriatic Arthritis
NCT01490450Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Dec 2011
- Primary completion
- Jun 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of clazakizumab in psoriatic arthritis (PsA), sponsored by CSL Limited. Started Dec 2011; status: completed.
02
Drugs
clazakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01490450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01490450.